NEW YORK (GenomeWeb News) – Epigenomics today announced preliminary revenue growth of 60 percent for full-year 2013.

Revenues for 2013 increased to €1.6 million ($2.2 million) from €1.0 million in 2012 on a strategic collaboration with BioChain in China and increased R&D service fees, the firm said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.